Withdrawal from long-term use of zopiclone, zolpidem and temazepam may improve perceived sleep and quality of life in older adults with primary insomnia.


Journal

Basic & clinical pharmacology & toxicology
ISSN: 1742-7843
Titre abrégé: Basic Clin Pharmacol Toxicol
Pays: England
ID NLM: 101208422

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 21 06 2018
accepted: 24 09 2018
pubmed: 9 10 2018
medline: 6 7 2019
entrez: 9 10 2018
Statut: ppublish

Résumé

Long-term use of benzodiazepines or benzodiazepine receptor agonists is widespread, although guidelines recommend short-term use. Only few controlled studies have characterized the effect of discontinuation of their chronic use on sleep and quality of life. We studied perceived sleep and quality of life in 92 older (age 55-91 years) outpatients with primary insomnia before and after withdrawal from long-term use of zopiclone, zolpidem or temazepam (BZDA). BZDA was withdrawn during 1 month, during which the participants received psychosocial support and blindly melatonin or placebo. A questionnaire was used to study perceived sleep and quality of life before withdrawal, and 1 month and 6 months later. 89 participants completed the 6-month follow-up. As melatonin did not improve withdrawal, all participants were pooled and then separated based solely on the withdrawal results at 6 months (34 Withdrawers. 55 Nonwithdrawers) for this secondary analysis. At 6 months, the Withdrawers had significantly (P < 0.05) shorter sleep-onset latency and less difficulty in initiating sleep than at baseline and when compared to Nonwithdrawers. Compared to baseline, both Withdrawers and Nonwithdrawers had at 6 months significantly (P < 0.05) less fatigue during the morning and daytime. Stress was alleviated more in Withdrawers than in Nonwithdrawers (P < 0.05). Satisfaction with life and expected health 1 year later improved (P < 0.05) in Withdrawers. In conclusion, sleep disturbances, daytime fatigue and impaired quality of life may resolve within 6 months of BZDA withdrawal. These results encourage withdrawal from chronic use of benzodiazepine-type hypnotics, particularly in older subjects.

Identifiants

pubmed: 30295409
doi: 10.1111/bcpt.13144
doi:

Substances chimiques

Azabicyclo Compounds 0
Hypnotics and Sedatives 0
Piperazines 0
Sleep Aids, Pharmaceutical 0
zopiclone 03A5ORL08Q
Zolpidem 7K383OQI23
Temazepam CHB1QD2QSS
Melatonin JL5DK93RCL

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

330-340

Subventions

Organisme : Finnish Cultural Foundation
Organisme : Satakunta Hospital District Grant EVO
Organisme : Southwest Finland Hospital District Grant EVO
Organisme : Härkätie Grant EVO

Informations de copyright

© 2018 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Auteurs

Ritva Lähteenmäki (R)

Department of Family Medicine, University of Turku, Turku, Finland.

Pertti J Neuvonen (PJ)

Department of Clinical Pharmacology, University of Helsinki, and HUSLAB, Helsinki University Hospital, Helsinki, Finland.

Juha Puustinen (J)

Unit of Neurology, Satakunta Hospital District, Pori, Finland.
Division of Pharmacology and Pharmacotherapy, Clinical Pharmacy Group, University of Helsinki, Helsinki, Finland.

Tero Vahlberg (T)

Department of Biostatistics, University of Turku, Turku, Finland.

Markku Partinen (M)

Helsinki Sleep Clinic, Vitalmed Research Center, Helsinki, Finland.
Department of Neurology, University of Helsinki, Helsinki, Finland.

Ismo Räihä (I)

Department of Family Medicine, University of Turku, Turku, Finland.

Sirkka-Liisa Kivelä (SL)

Department of Family Medicine, University of Turku, Turku, Finland.
Division of Pharmacology and Pharmacotherapy, Clinical Pharmacy Group, University of Helsinki, Helsinki, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH